article thumbnail

FDA prioritizes guidance on AI, cybersecurity, pulse oximeters in stacked schedule for 2024

Healthcare Dive

The administration is ramping up production of medtech guidance, adding 18 draft documents to the list of priorities for the upcoming financial year.

FDA 317
article thumbnail

Petrie-Flom Welcomes 2023-2024 Student Fellows

Bill of Health

2024) in the Berkeley-Harvard Exchange Program. His current research focuses on tensions between the patent incentive system, the FDA approval process, and insurance carriers. The post Petrie-Flom Welcomes 2023-2024 Student Fellows first appeared on Bill of Health. Keep an eye out for their bylines!

Bioethics 144
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Digital Health at CES 2024

Healthcare IT Today

Digital Health Media Panel at CES 2024 First up was a fun Digital Health media panel that I participated in on the CTA Center Stage with Eric Wicklund , Content Specialist at HealthLeaders Media, Savannah Peterson , Host at theCUBE, and Grace Venes-Escaffi , Sr. Here’s a look at how their demo worked for me.

FDA 117
article thumbnail

FDA Forms Digital Health Advisory Committee

HIT Consultant

– The Digital Health Advisory Committee will advise the FDA on issues related to DHTs, providing relevant expertise and perspective to help improve the agency’s understanding of the benefits, risks, and clinical outcomes associated with use of DHTs. . The committee should be fully operational in 2024. “As

FDA 105
article thumbnail

Samsung Galaxy Watch Receives FDA Nod for Sleep Apnea Detection

HIT Consultant

What You Should Know: – Samsung’s Galaxy Watch has received De Novo authorization from the US Food and Drug Administration (FDA) for its sleep apnea detection feature. – This marks a significant step forward in wearable technology, making it the first of its kind to be approved by the FDA for detecting potential sleep apnea.

FDA 98
article thumbnail

23andMe Scores FDA Clearance for Novel Cancer Immunotherapy Targeting NK Cells

HIT Consultant

Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for 23ME-01473 (referred to as ‘1473), paving the way for the first human clinical trial of this promising new therapy. – With FDA clearance secured, 23andMe plans to initiate a Phase 1 clinical trial in the first half of 2024.

FDA 104
article thumbnail

Healthcare Cybersecurity – 2024 Health IT Predictions

Healthcare IT Today

As we kick off 2024, we wanted to start the new year with a series of 2024 Health IT predictions. In 2024, the attack surface will continue to grow. I expect that to intensify further throughout 2024. In fact, we got so many that we had to narrow them down to just the best and most interesting.